ALVIO Stock Overview
A clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Valerio Therapeutics Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.08 |
| 52 Week High | €0.18 |
| 52 Week Low | €0.065 |
| Beta | 1.72 |
| 11 Month Change | -6.35% |
| 3 Month Change | -3.39% |
| 1 Year Change | -53.66% |
| 33 Year Change | -80.91% |
| 5 Year Change | -85.54% |
| Change since IPO | -99.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALVIO | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -0.4% | -7.7% | -0.3% |
| 1Y | -53.7% | -26.4% | -3.5% |
Return vs Industry: ALVIO underperformed the French Biotechs industry which returned -26.4% over the past year.
Return vs Market: ALVIO underperformed the French Market which returned -3.5% over the past year.
Price Volatility
| ALVIO volatility | |
|---|---|
| ALVIO Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALVIO's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALVIO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 38 | Julien Miara | valeriotx.com |
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops AsiDNA, which is in Phase 1b/2 trial in combination with the PARP inhibitor Olaparib to evaluate safety in patients with epithelial ovarian cancer, breast cancer, and metastatic castration-resistant prostate cancer. It also develops Revocan that is in Phase 1b/2 trial to evaluate the addition of AsiDNA to combat PARP inhibitor resistance in second-line maintenance treatment of recurrent ovarian cancer, as well as in phase 1b/2 trial evaluating AsiDNA in combination with radiotherapy in recurrent highgrade glioma in children.
Valerio Therapeutics Société anonyme Fundamentals Summary
| ALVIO fundamental statistics | |
|---|---|
| Market cap | €11.21m |
| Earnings (TTM) | -€19.66m |
| Revenue (TTM) | €1.89m |
6.5x
P/S Ratio-0.6x
P/E RatioIs ALVIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALVIO income statement (TTM) | |
|---|---|
| Revenue | €1.89m |
| Cost of Revenue | €477.00k |
| Gross Profit | €1.41m |
| Other Expenses | €21.07m |
| Earnings | -€19.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 74.75% |
| Net Profit Margin | -1,040.66% |
| Debt/Equity Ratio | 317.0% |
How did ALVIO perform over the long term?
See historical performance and comparison